Decentralised European approval for Shire's Vyvanse for ADHD

20 Dec 2012

• By Pial Ganguli

Shire has received European approval of Vyvanse (lisdexamfetamine dimesylate, to be known as Elvanse, or Tyvense in Ireland) for attention deficit/hyperactivity disorder (ADHD) via the decentralised procedure.

The drug is now indicated for use as part of a comprehensive treatment program for ADHD in children aged 6...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

04 Jun 2025

• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

03 Jun 2025

• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

02 Jun 2025

• By Kevin Grogan

But the French major is still keen on early-stage M&A.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

30 May 2025

• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.